- Home
- ASB vs DNLI Comparison
ASB vs DNLI Comparison
Compare ASB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASB
- DNLI
- Stock Information
- Founded
- ASB 1861
- DNLI 2013
- Country
- ASB United States
- DNLI United States
- Employees
- ASB N/A
- DNLI N/A
- Industry
- ASB Major Banks
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASB Finance
- DNLI Health Care
- Exchange
- ASB Nasdaq
- DNLI Nasdaq
- Market Cap
- ASB 3.3B
- DNLI 2.4B
- IPO Year
- ASB N/A
- DNLI 2017
- Fundamental
- Price
- ASB $21.21
- DNLI $14.89
- Analyst Decision
- ASB Hold
- DNLI Strong Buy
- Analyst Count
- ASB 10
- DNLI 16
- Target Price
- ASB $27.20
- DNLI $37.57
- AVG Volume (30 Days)
- ASB 1.6M
- DNLI 1.3M
- Earning Date
- ASB 04-24-2025
- DNLI 05-06-2025
- Dividend Yield
- ASB 4.31%
- DNLI N/A
- EPS Growth
- ASB N/A
- DNLI N/A
- EPS
- ASB 0.72
- DNLI N/A
- Revenue
- ASB $952,855,000.00
- DNLI N/A
- Revenue This Year
- ASB $54.38
- DNLI N/A
- Revenue Next Year
- ASB $5.85
- DNLI $497.02
- P/E Ratio
- ASB $29.65
- DNLI N/A
- Revenue Growth
- ASB N/A
- DNLI N/A
- 52 Week Low
- ASB $19.76
- DNLI $14.01
- 52 Week High
- ASB $28.18
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ASB 27.80
- DNLI 31.61
- Support Level
- ASB $20.94
- DNLI $14.20
- Resistance Level
- ASB $25.03
- DNLI $16.28
- Average True Range (ATR)
- ASB 0.72
- DNLI 1.39
- MACD
- ASB -0.33
- DNLI -0.22
- Stochastic Oscillator
- ASB 6.60
- DNLI 12.66
About ASB Associated Banc-Corp
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.